Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Latest News
    • FDA OKs Merck drug...

    FDA OKs Merck drug that prevents infection post-stem cell transplant

    Written by Ruby Khatun Khatun Published On 2017-11-11T10:01:27+05:30  |  Updated On 18 Aug 2021 2:53 PM IST

    Merck & Co Ltd's drug to prevent serious infection in patients who undergo a type of stem cell transplant was approved by the U.S. Food and Drug Administration, the drugmaker said on Thursday.


    Merck said the drug, which is expected to be available from December, was approved both as a tablet and an injection. The list price for the tablets is $195 per day, while it is $270 a day for the injection.


    The recommended dosing for the drug is once every day for 100 days after the stem cell transplant, bringing the effective list price to $19,500 for the tablets and $27,000 for the injections.


    The list price of a drug is not necessarily what patients actually pay. "Out-of-pocket" costs vary based on the duration of the treatment and individual healthcare plans.


    Merck's drug, Prevymis, was approved to prevent cytomegalovirus (CMV) infection - a complication associated with bone marrow transplants that treat acute leukemias, other cancers, and diseases of the bone marrow.


    CMV can occur in patients who have undergone a transplant of hematopoietic stem cells, which are located in the bone marrow and derived from a donor.


    While there are other drugs that treat CMV once it occurs, attempts to find a safe drug that can prevent it had failed.




    (Reporting by Manas Mishra in Bengaluru; Editing by Sai Sachin Ravikumar)



    acute leukemiasapprovalbone marrowbone marrow transplantscancersCytomegalovirusdrugFDAinfectionInjectionMerckpharma newsPrevymisstem cell transplanttabletU.S. Food and Drug Administration
    Source : REUTERS

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Ruby Khatun Khatun
    Ruby Khatun Khatun
      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok